Author Archives: admin


Canine Stem Cell Therapy Market to Witness Growth Acceleration | Aratana Therapeutics, Okyanos, Magellan Stem Cells Travel Adventure Cinema – Travel…

New Jersey (United States) A2Z Market Research published new research on Global Canine Stem Cell Therapy covering the micro-level of analysis by competitors and key business segments (2022-2029). The Global Canine Stem Cell Therapy explores a comprehensive study on various segments like opportunities, size, development, innovation, sales, and overall growth of major players. The research is carried out on primary and secondary statistics sources and it consists of both qualitative and quantitative detailing.

Some of the Major Key players profiled in the study are Aratana Therapeutics, Okyanos, Magellan Stem Cells, Stem Cell Vet, VetStem Biopharma, Medrego, Regeneus Ltd, MediVet Biologic, Cell Therapy Sciences

Get PDF Sample Report + All Related Table and Graphs @:

The global Canine Stem Cell Therapy Market research report delivers a comprehensive analysis of market size, market trends, and market growth prospects. This report also delivers extensive information on the technology expenditure for the forecast period, which gives a unique view of the global Canine Stem Cell Therapy Market across numerous segments. The global Canine Stem Cell Therapy market report also allows consumers recognize market prospects and challenges.

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global

Global Canine Stem Cell Therapy Market Segmentation:

Market Segmentation: By Type

Allogeneic Stem Cells, Autologous Stem Cells

Market Segmentation: By Application

Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes

Key market aspects are illuminated in the report:

Executive Summary: It covers a summary of the most vital studies, the Global Canine Stem Cell Therapy market increasing rate, modest circumstances, market trends, drivers and problems as well as macroscopic pointers.

Study Analysis: Covers major companies, vital market segments, the scope of the products offered in the Global Canine Stem Cell Therapy market, the years measured, and the study points.

Company Profile: Each Firm well-defined in this segment is screened based on a products, value, SWOT analysis, their ability and other significant features.

Manufacture by region: This Global Canine Stem Cell Therapy report offers data on imports and exports, sales, production and key companies in all studied regional markets

Get Special pricing with up to 30% Discount on the first purchase of this report @:

The cost analysis of the Global Canine Stem Cell Therapy Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Highlighting points of Global Canine Stem Cell Therapy Market Report:

Table of Contents

Global Canine Stem Cell Therapy Market Research Report 2022 2029

Chapter 1 Canine Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Canine Stem Cell Therapy Market Forecast

Buy the Full Research Report of Global Canine Stem Cell Therapy Market @: :

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

+1 775 237 4147

See the rest here:
Canine Stem Cell Therapy Market to Witness Growth Acceleration | Aratana Therapeutics, Okyanos, Magellan Stem Cells Travel Adventure Cinema - Travel...

Gov. Whitmer announces more budget vetoes, mostly tied to curbs on abortion rights – Detroit Free Press

Show Caption

Hide Caption

Attorney General Dana Nessel discusses Supreme Court ruling on abortion

Nessel has pledged not to enforce Michigan's highly restrictive 1931 abortion law, should it take effect after Friday's U.S. Supreme Court ruling.

Provided by the Michigan Department of the Attorney General

LANSING Gov. Gretchen Whitmer'soffice on Monday detailed more than $20 million in line-item vetoes she plans to make to the state's main 2023 budget billwhen she signs it into law Wednesday.

Most of the vetoed budget itemsin House Bill 5783 relate to the Department of Health and Human Services and involve restrictions on the use of state funds to pay for abortionsor funding for pregnancy and parenting centers that promote alternatives to abortion.Whitmer also vetoed a $2 million tax credit for adoptive parents, a $10 million marketing program to promote adoption as an alternative to abortion, and a $100,000 legal fund in the Michigan Department of Corrections to pay for efforts to prevent the use of state funds for gender-confirmationsurgery or therapies in state prisons.

The announcement drew swift criticism from Republicans. The governor claims to be a voice for choice, but her actions clearly support only one option for women in a crisis pregnancy the deadly choice of abortion," said State Rep. Thomas Albert, R-Lowell, chairman of the House Appropriations Committee.

Monday's announcement follows Whitmer's vetoes Thursday of $6 million from the education budget. The money funded college and university pregnancy and parenting centers that would be prohibited from making abortion referrals and money for "ethical stem cell/tissue research" that would place restrictions on which stem cells and human embryos could be used.

On Wednesday, Whitmer "is expected to veto funding for centers that often purport to offer comprehensive reproductive health care, including abortion, but dont, preying on women at a vulnerable time in their lives," Whitmer spokesman Bobby Leddy said.

The centers, which Leddy said are sometimes known as fake womens health centers or pregnancy resource centers, frequentlyuse deceptive advertising that target young women and women with low incomes who are seeking abortion care, painting themselves as comprehensive, licensed health care clinics that provide all options, and then lie to women about medical facts," Leddy said.

Whitmer "supports legislation that provides every possible resource to women who are pregnant, seeking to start a family, or those who arent ready yet, but she cannot support aspects of a bill that sends millions in taxpayer dollars to fake health centers that intentionally withhold information from women about their health, bodies, and full reproductive freedom," Leddy said.

The budget, approved overwhelmingly by lawmakers from both parties, was the product of negotiations and a consensus the governor reached with Republican legislative leaders. Still, none of the leaders should be surprised by any of the vetoes, Leddy said.

Gideon D'Assandro, a spokesman for House Speaker Jason Wentworth, R-Farwell, confirmed the vetoes are not a surprise.

More: Whitmer vetoes budget items restricting abortion access, stem cell research

More: Whitmer signs $22.2B budget for Michigan K-12 schools, colleges and universities

Albertsaid it is shocking that"helping pregnant women who might consider adoption instead is now a bridge too far," and the vetoes remove help for "expecting mothers and their babies, including those facing a crisis pregnancy, by denying them access to essential care both before and after giving birth."

Whitmer is usingher line-item veto powers for budget bills as tensions are high between herand the Republican-controlled Legislature after the U.S. Supreme Court struck down Roe v. Wade, which recognized abortion rights.

The toppling of Roe would put into effect a 1931 state law that prohibits abortions except to save the life of the mother, but a Court of Claims judge has temporarily preserved the status quo by issuing an injunction against the 1931 law. Whitmer has asked the Michigan Supreme Court to declare that the law violates the state constitution; Republicans are fighting to preserve the law.

Contact Paul Egan: 517-372-8660 or pegan@freepress.com.Follow him on Twitter @paulegan4. Read more on Michigan politics and sign up for our elections newsletter.

Become asubscriber.

Read more:
Gov. Whitmer announces more budget vetoes, mostly tied to curbs on abortion rights - Detroit Free Press

Embryonic Research Could Be the Next Target After Roe – WIRED

Two weeks after the US Supreme Court overturned the federal right to an abortion, Ye Yuan heard from a woman who wanted to reverse her decision to donate her embryos to scientific research. The womanwho contacted Yuan anonymously through a fertility counselorwas fearful that if the law in Colorado changed to make it illegal to discard or experiment on human embryos, then she would be forced to have hers frozen indefinitely. In a year, or five years, might a law change to stop her from having the final say over what happened to them?

This content can also be viewed on the site it originates from.

In states where human embryonic research is legal, people undergoing IVF are often given the choice to donate any excess fertilized embryos to scientific research. These are sometimes used to search for potential treatments for diseases such as diabetes or, as in Yuans case, to research ways to make IVF more successful. Those discarded embryos are really one of the key pieces for us to maintain the high quality of our platform here, says Yuan, who is research director at the Colorado Center for Reproductive Medicine (CCRM). But in the wake of the Dobbs verdict, he is worried that people will be less likely to donate their spare embryos for research and, down the line, that embryonic research could become the next target of antiabortion campaigners.

Its like youre a little girl living in a dark room. You know there are bad guys outside but youre not too worried because the door has been locked, says Yuan. But then somebody tells you that the door has been unlocked. Yuan fears that anything that slows down access to human embryos will ultimately end up slowing progress in IVF, which is responsible for between 1 and 2 percent of all US births annually.

The majority opinion written by Justice Samuel Alito doesnt single out IVF or human embryonic research, but his choice of words to describe abortion could be seen as also being applicable to embryos outside the body, says Glenn Cohen, a bioethicist and professor of law at Harvard Law School. The right to an abortion is distinct from other rights, Alito notes in the opinion, because it destroys potential life and the life of an unborn human being.

The same thing that he uses to distinguish abortion seems to me completely applicable to distinguishing embryos, says Cohen. To me it makes it very, very clear after Dobbs that any state that wants to prohibit the destruction of embryos as part of research is free to do so.

The wording that legislators use to describe the beginning of human life is also important. In at least nine states, trigger lawspieces of legislation designed to restrict abortion quickly after the fall of Roeinclude language that implies an egg cell becomes an unborn child or unborn human being at the precise moment of fertilization. In other words, according to these definitions, every single human embryoincluding donated embryos that might be used in scientific researchis an unborn child. Although most of these trigger laws apply specifically to pregnancy, and so do not regulate embryos outside of the human body, the idea that life begins at the very moment of fertilization could be used to target embryonic research, says Cohen. If you have that view, its not clear to me why you would exempt the destruction of embryos if you prohibit abortion. To me, that wrong is the same.

Read the original:
Embryonic Research Could Be the Next Target After Roe - WIRED

Cell Culture Media Market: Competitive Approach, Breakdown And Forecast by 2027 – Digital Journal

Market Overview

Thecell culture media marketis expected to cross USD 4.33 billion by 2027 at a CAGR of8.33%.

Market Dynamics

The markets growth is being fueled by a diverse range of cell culture media applications, increased research and development in the pharmaceutical industry, an increase in the prevalence of chronic diseases, and increased expansion and product launches by major players. Over the last few decades, advancements in cell culture technology have accelerated. It is widely regarded as one of the most dependable, robust, and mature technologies for biotherapeutic product development.

The high cost of cell culture media and the risk of contamination, on the other hand, are impeding the markets growth. However, the growing emphasis on regenerative and personalized medicine is likely to spur growth in the global cell culture media market.

Get Sample Report: https://www.marketresearchfuture.com/sample_request/4462

Competitive Dynamics

The notable players are the Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), GE Healthcare (US), Becton, Dickinson and Company (US), HiMedia Laboratories (India), Corning Incorporated (US), PromoCell (Germany), Sera Scandia A/S (Denmark), The Sartorius Group (Germany), and Fujifilm Holdings Corporation (Japan).

Segmental Analysis

The global market for cell culture media has been segmented according to product type, application, and end user.

The market has been segmented by product type into classical media, stem cell media, serum-free media, and others.

Further subcategories of stem cell culture media include bone marrow, embryonic stem cells, mesenchymal stem cells, and neural stem cells.

The market is segmented into four application segments: drug discovery and development, cancer research, genetic engineering, and tissue engineering and biochemistry.

The market is segmented by end user into biochemistry and pharmaceutical companies, research laboratories, academic institutions, and pathology laboratories.

Regional Overview

According to region, the global cell culture media market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas dominated the global cell culture media market. The large share is attributed to the presence of major manufacturers, rising disease prevalence resulting in increased demand for drugs and other medications, technological advancements in the preclinical and clinical segments, growing public awareness, and high disposable income.

Europe ranks second in terms of market size for cell culture media. Factors such as an increase in the biopharmaceutical sector in the European region, increased government initiatives to promote research to find a cure for the growing number of chronic diseases, an increase in the number of pharmaceutical manufacturers, improving economies, a high disposable income per individual, and increased healthcare spending are all contributing to the markets growth in this region. The European market is expected to be driven by expanding R&D activities and a developing biopharmaceutical sector.

Asia-Pacific held the third-largest market share, owing to the presence of numerous research organizations, low manufacturing costs, low labor costs, developing healthcare infrastructure, and increased investment by American and European market giants in Asian countries such as China and India.

The Middle East and Africa, with limited economic development and extremely low income, held the smallest market share in 2019 but is expected to grow due to growing public awareness and demand for improved healthcare facilities in countries, as well as rising disposable income.

Browse Full Reports: https://www.marketresearchfuture.com/reports/cell-culture-media-market-4462

Related Report: Dysmenorrhea Treatment Market Research Report- Global Forecast to 2027

Syringe and Needle Market Research Report Global Forecast to 2027

Global Medical Robotics Market Research Report- Forecast To 2027

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

See the article here:
Cell Culture Media Market: Competitive Approach, Breakdown And Forecast by 2027 - Digital Journal

Stem Cell Therapy Market Size, Scope, Growth Opportunities, Trends by Manufacturers And Forecast to 2029 This Is Ardee – This Is Ardee

New Jersey, United States TheStem Cell TherapyMarket research guides new entrants to obtain precise market data and communicates with customers to know their requirements and preferences. It spots outright business opportunities and helps to bring new products into the market. It identifies opportunities in the marketplace. It aims at doing modifications in the business to make business procedures smooth and make business forward. It helps business players to make sound decision making. Stem Cell Therapy market report helps to reduce business risks and provides ways to deal with upcoming challenges. Market information provided here helps new entrants to take informed decisions making. It emphasizes on major regions of the globe such as Europe, North America, Asia Pacific, Middle East, Africa, and Latin America along with their market size.

Such unique Stem Cell Therapy Market research report offers some extensive strategic plans that help the players to deal with the current market situation and make your position. It helps in strengthening your business position. It offers better understanding of the market and keep perspective to aid one remain ahead in this competitive market. Organizations can gauze and compare their presentation with others in the market on the basis of this prompt market report. This market report offers a clarified picture of the varying market tactics and thereby helps the business organizations gain bigger profits. You get a clear idea about the product launches, trade regulations and expansion of the market place through this market report.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=24113

Key Players Mentioned in the Stem Cell Therapy Market Research Report:

Osiris Therapeutics Medipost Co. Ltd., Anterogen Co. Ltd., Pharmicell Co. Ltd., HolostemTerapieAvanzateSrl, JCR Pharmaceuticals Co. Ltd., Nuvasive RTI Surgical Allosource

Stem Cell TherapyMarket report consists of important data about the entire market environment of products or services offered by different industry players. It enables industries to know the market scenario of a particular product or service including demand, supply, market structure, pricing structure, and trend analysis. It is of great assistance in the product market development. It further depicts essential data regarding customers, products, competition, and market growth factors. Stem Cell Therapy market research benefits greatly to make the proper decision. Future trends are also revealed for particular products or services to help business players in making the right investment and launching products into the market.

Stem Cell TherapyMarket Segmentation:

Stem Cell Therapy Market, By Cell Source

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

Stem Cell Therapy Market, By Therapeutic Application

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

Stem Cell Therapy Market, By Type

Allogeneic Stem Cell Therapy Autologous Stem Cell Therapy

Inquire for a Discount on this Premium Report@ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113

For Prepare TOC Our Analyst deep Researched the Following Things:

Report Overview:It includes major players of the Stem Cell Therapy market covered in the research study, research scope, market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the Stem Cell Therapy market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the Stem Cell Therapy market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the Stem Cell Therapy market by application, it gives a study on the consumption in the Stem Cell Therapy market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the Stem Cell Therapy market are profiled in this section. The analysts have provided information about their recent developments in the Stem Cell Therapy market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the Stem Cell Therapy market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the Stem Cell Therapy market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the Stem Cell Therapy market.

Key Findings:This section gives a quick look at the important findings of the research study.

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/stem-cell-therapy-market/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080 UK: +44 (753)-715-0008 APAC: +61 (488)-85-9400 US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Read the original:
Stem Cell Therapy Market Size, Scope, Growth Opportunities, Trends by Manufacturers And Forecast to 2029 This Is Ardee - This Is Ardee

Human iPSC co-culture model to investigate the interaction between microglia and motor neurons | Scientific Reports – Nature.com

Ethics statement

All human material (blood RNA, primary microglia RNA, iPSCs) used in this study was derived after signed informed consent: for blood, according to University of Oxford OHS policy document 1/03; all procedures related to the use of the primary microglia followed established institutional (McGill University, Montreal, QC, Canada) and Canadian Institutes of Health Research guidelines for the use of human cells; for iPSC, with approval from the South Central Berkshire Research Ethics Committee, U.K. (REC 10/H0505/71). The blood RNA and primary microglia RNA samples have been published previously26, as have the iPSC lines (see below).

Four healthy control iPSC lines, SFC840-03-03 (female, 67years old,35), SFC841-03-01 (male, 36,18), SFC856-03-04 (female, 78,36), OX3-06 (male, 49,37), generated from skin biopsy fibroblasts and characterized as described before, were used in this study. Additionally, the previously reported26 line AH016-3 Lenti_IP_RFP (male, 80years old), which constitutively expresses Red Fluorescent Protein (RFP) under continuous puromycin selection, was used for some live-imaging experiments.

iPSCs were cultured in mTeSR1 (StemCell Technologies) or OXE8 medium38 on Geltrex (Thermo Fisher)-coated tissue culture plates with daily medium changes. Passaging was done as clumps using EDTA in PBS (0.5mM). Cells were initially expanded at low passage to create a master stock, which was used for all experiments to ensure consistency. Cells were regularly tested negative for mycoplasma using MycoAlert Mycoplasma Detection Kit (Lonza).

iPSCs were differentiated to MNs according to our previously published protocol18,19,27. Briefly, neural induction of iPSC monolayers was performed using DMEM-F12/Neurobasal 50:50 medium supplemented with N2 (1X), B27 (1X), 2-Mercaptoethanol (1X), AntibioticAntimycotic (1X, all ThermoFisher), Ascorbic Acid (0.5M), Compound C (1M, both Merck), and Chir99021 (3M, R&D Systems). After two days in culture, Retinoic Acid (RA, 1M, Merck) and Smoothened Agonist (SAG, 500nM, R&D Systems) were additionally added to the medium. Two days later, Compound C and Chir99021 were removed from the medium. After another 5days in culture, neural precursors were dissociated using accutase (ThermoFisher), and split 1:3 onto Geltrex-coated tissue culture plates in medium supplemented with Y-27632 dihydrochloride (10M, R&D Systems). After one day, Y-27632 dihydrochloride was removed from the medium, and then the cells were cultured for another 8days with medium changes every other day. For terminal maturation, the cells were dissociated on day in vitro (DIV) 18 using accutase and plated onto coverslips or tissue culture plates coated with polyethylenimine (PEI, 0.07%, Merck) and Geltrex or tissue culture dishes coated with PDL (Sigma-Aldrich)/ Laminin (R&D Systems)/ Fibronectin (Corning). For this step, the medium was additionally supplemented with BDNF (10ng/mL), GDNF (10ng/mL), Laminin (0.5g/mL, all ThermoFisher), Y-27632 dihydrochloride (10M), and DAPT (10M, R&D Systems). Three days later, Y-27632 dihydrochloride was removed from the medium. After another three days, DAPT was removed from the medium. Full medium changes were then performed every three days.

For MNs differentiated in co-culture medium alone, all steps were performed similarly until three days after the terminal re-plating (D21). MNs were then cultured in co-culture medium as described below.

iPSCs were differentiated to macrophage/microglia precursors as described previously20,21. Briefly, embryoid body (EB) formation was induced by seeding iPSCs into Aggrewell 800 wells (STEMCELL Technologies) in OXE838 or mTeSR1 medium supplemented with Bone Morphogenetic Protein 4 (BMP4, 50ng/mL), Vascular Endothelial Growth Factor (VEGF, 50ng/mL, both Peprotech), and Stem Cell Factor (SCF, 20ng/mL, Miltenyi Biotec). After four days with daily medium changes, EBs were transferred to T175 flasks (~150 EBs each) and differentiated in X-VIVO15 (Lonza), supplemented with Interleukin-3 (IL-3, 25ng/mL, R&D Systems), Macrophage Colony-Stimulating Factor (M-CSF, 100ng/mL), GlutaMAX (1X, both ThermoFisher), and 2-Mercaptoethanol (1X). Fresh medium was added weekly. After approximately one month, precursors emerged into the supernatant and could be harvested weekly. Harvested cells were passed through a cell strainer (40M, Falcon) and either lysed directly for RNA extraction or differentiated to microglia in monoculture or co-culture as described below.

Three days after the final re-plating of differentiating MNs (DIV21), macrophage/microglia precursors were harvested as described above and resuspended in co-culture medium comprised of Advanced DMEM-F12 (ThermoFisher) supplemented with GlutaMAX (1X), N2 (1X), AntibioticAntimycotic (1X), 2-Mercaptoethanol (1X), Interleukin-34 (IL-34, 100ng/mL, Peprotech), BDNF (10ng/mL), GDNF (10ng/mL), and Laminin (0.5g/mL). MNs were quickly rinsed with PBS, and macrophage/microglia precursors re-suspended in co-culture medium were added to each well. Co-cultures were then maintained for at least 14days before assays were conducted as described below. Half medium changes were performed every 23days.

For comparisons between co-cultures and monocultures, MNs and monocultured microglia were also differentiated alone in co-culture medium.

Cells cultured on coverslips were pre-fixed with 2% paraformaldehyde in PBS for 2min and then fixed with 4% paraformaldehyde in PBS for 15min at room temperature (RT). After permeabilization and blocking with 5% donkey/goat serum and 0.2% Triton X-100 in PBS for 1h at RT, the coverslips were incubated with primary antibodies diluted in 1% donkey/goat serum and 0.1% Triton X-100 in PBS at 4C ON. The following primary antibodies were used: rabbit anti-cleaved caspase 3 (1:400, 9661S, Cell Signaling), mouse anti-ISLET1 (1:50, 40.2D6, Developmental Studies Hybridoma Bank), mouse anti-TUJ1 (1:500, 801201, BioLegend), rabbit anti-TUJ1 (1:500, 802001, BioLegend), chicken anti-TUJ1 (1:500, GTX85469, GeneTex), rabbit anti-IBA1 (1:500, 019-19741, FUJIFILM Wako Pure Chemical Corporation), goat anti-IBA1 (1:500, ab5076, abcam), rabbit anti-synaptophysin (1:200, ab14692, abcam), goat anti-ChAT (1:100, ab114P, abcam), rat anti-TREM2 (1:100, MAB17291-100, R&D Systems), rabbit anti-TMEM119 (1:100, ab185337, abcam), rat anti-CD11b (1:100, 101202, BioLegend).

After three washes with PBS-0.1% Triton X-100 for 5min each, coverslips were incubated with corresponding fluorescent secondary antibodies Alexa Fluor 488/568/647 donkey anti-mouse/rabbit/rat/goat, goat anti-chicken (all 1:1000, all ThermoFisher). Coverslips were then washed twice with PBS-0.1% Triton X-100 for 5min each and incubated with 4,6-diamidino-2-phenylindole (DAPI, 1g/mL, Sigma-Aldrich) in PBS for 10min. After an additional 5min-washing step with PBS-0.1% Triton X-100, the coverslips were mounted onto microscopy slides using ProLong Diamond Antifade Mountant (ThermoFisher). Confocal microscopy was then performed using an LSM 710 microscope (Zeiss).

For the analysis of neuronal and MN markers after differentiation, three z-stacks (2m intervals) of randomly selected visual fields (425.1425.1m) were taken for each coverslip at 20magnification. The ratios of TUJ1-positive, ChAT-positive, ISLET1-positive, ChAT-positive/ TUJ1-positive, and ISLET1-positive/ TUJ1-positive cells were then quantified using Fiji in a blinded fashion.

For the analysis of microglial markers in monoculture and co-culture, three z-stacks (1m intervals) of randomly selected visual fields (212.55212.55m) were taken for each coverslip at 40magnification. The expression of CD11b, TMEM119, and TREM2 in IBA1-positive cells in monoculture and co-culture was then quantified using Fiji.

For the analysis of apoptosis in neurons, five z-stacks images of randomly selected visual fields (212.55212.55m) were taken at 40magnification for each coverslip. The ratios of cleaved caspase 3/ TUJ1-positive cells were then quantified for neurons in monoculture and co-culture in a blinded fashion. For the analysis of apoptosis in microglia, three z-stacks images of randomly selected visual fields (212.55212.55m) were taken at 40magnification for each coverslip. The ratios of cleaved caspase 3/ IBA1-positive cells were then quantified for microglia in monoculture and co-culture.

For the analysis of microglial ramifications, five z-stacks images of randomly selected visual fields (212.55212.55m) were taken at 40magnification for each coverslip. To analyze the branching of IBA1-positive microglia in monoculture and co-culture, the average branch length, number of branch points and number of branch endpoints was determined using 3DMorph39, a Matlab-based script for the automated analysis of microglial morphology.

From the same harvest, macrophage precursors (pMacpre) were either lysed directly or differentiated to microglia in monoculture (pMGL) or microglia in co-culture with MNs (co-pMG) for 14days. pMGL were rinsed with PBS and directly lysed in the dish. For both pMacpre and pMGL, RNA was extracted using an RNAeasy Mini Plus kit (Qiagen) according to the manufacturers instructions. Co-cultures were first dissociated by 15min incubation with papain (P4762, Sigma-Aldrich) diluted in accutase (20 U/mL) and gentle trituration based on a previously published protocol40. The cell suspension was then passed through a cell strainer (70m, Falcon) to remove cell clumps. To extract co-pMG, magnetic-activated cell sorting (MACS) was then performed using CD11b-MACS beads (130093-634, Miltenyi Biotec) according to the manufacturers instructions. The panned cell population was lysed for RNA extraction using an RNAeasy Micro kit (Qiagen) according to the manufacturers instructions. In addition, RNA from human fetal microglia and blood monocytes from three different healthy genetic backgrounds wasre-used from our previous study26.

RNA from the four different healthy control lines (listed earlier) per condition (pMacpre, pMGL, co-pMG) was used for RNA sequencing analysis. Material was quantified using RiboGreen (Invitrogen) on the FLUOstar OPTIMA plate reader (BMG Labtech) and the size profile and integrity analysed on the 2200 or 4200 TapeStation (Agilent, RNA ScreenTape). RIN estimates for all samples were between 9.2 and 9.9. Input material was normalised to 100ng prior to library preparation. Polyadenylated transcript enrichment and strand specific library preparation was completed using NEBNext Ultra II mRNA kit (NEB) following manufacturers instructions. Libraries were amplified (14 cycles) on a Tetrad (Bio-Rad) using in-house unique dual indexing primers (based on41). Individual libraries were normalised using Qubit, and the size profile was analysed on the 2200 or 4200 TapeStation. Individual libraries were normalised and pooled together accordingly. The pooled library was diluted to~10nM for storage. The 10nM library was denatured and further diluted prior to loading on the sequencer. Paired end sequencing was performed using a NovaSeq6000 platform (Illumina, NovaSeq 6000 S2/S4 reagent kit, v1.5, 300 cycles), generating a raw read count of a minimum of 34M reads per sample.

Further processing of the raw data was then performed using an in-house pipeline. For comparison, the RNA sequencing data (GSE89189) fromAbud et al.28 and the dataset (GSE85839) fromMuffat et al.29 were downloaded and processed in parallel. Quality control of fastq files was performed using FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and MultiQC42. Paired-end reads were mapped to the human GRCh38.p13 reference genome (https://www.gencodegenes.org) using HISAT2 v2.2.143. Mapping quality control was done using SAMtools44 and Picard (http://broadinstitute.github.io/picard/) metrics. The counts table was obtained using FeatureCounts v2.0.145. Normalization of counts and differential expression analysis for the comparison of pMGL and co-pMG was performed using DESeq2 v1.28.146 in RStudio 1.4.1103, including the biological gender in the model and with the BenjaminiHochberg method for multiple testing correction. Exploratory data analysis was performed following variance-stabilizing transformation of the counts table, using heat maps and hierarchical clustering with the pheatmap 1.0.12 package (https://github.com/raivokolde/pheatmap) and principal component analysis. Log2 fold change (log2 fc) shrinkage for the comparison of pMGL and co-pMG was performed using the ashr package v2.2-4747. Genes with |log2 fc|>2 and adjusted p value<0.01 were defined as differentially expressed and interpreted with annotations from the Gene Ontology database using clusterProfiler v3.16.148 to perform over-representation analyses.

Equal amounts of RNA (30ng) were reverse-transcribed to cDNA using the High-Capacity cDNA Reverse Transcription Kit (ThermoFisher) according to the manufacturers instructions. Quantitative real-time PCR was performed with Fast SYBR Green Master Mix (ThermoFisher) according to the manufacturers instructions using a LightCycler 480 PCR System (Roche). The following primers (ChAT from Eurofins Genomics, all others from ThermoFisher) were used:

Quantification of the relative fold gene expression of samples was performed using the 2Ct method with normalization to the GAPDH reference gene.

AH016-3 Lenti-IP-RFP-microglia were co-cultured with healthy control motor neurons in PEI- and Geltrex-coated glass bottom dishes for confocal microscopy (VWR). The RFP signal was used to identify microglia in co-culture. To visualize microglial movement, images of the RFP signal and brightfield were taken every~30s for 1h (22 stitched images, 20magnification) using a Cell Observer spinning disc confocal microscope (Zeiss) equipped with an incubation system (37C, 5% CO2). To image phagocytic activity, co-cultures were rinsed with Live Cell Imaging Solution (1X, ThermoFisher), and pHrodo Green Zymosan Bioparticles Conjugates (P35365, ThermoFisher) diluted in Live Cell Imaging Solution (50g/mL), which become fluorescent upon phagocytic uptake, were added. The dish was immediately transferred to the spinning disc confocal microscope, and stitched images (33, 20magnification) were acquired every 5min for 2h.

To induce pro-inflammatory (M1) or anti-inflammatory (M2) microglial phenotypes, cells were treated with Lipopolysaccharides (LPS, 100ng/mL, Sigma) and Interferon- (IFN-, 100ng/mL, ThermoFisher), or Interleukin-4 (IL-4, 40ng/mL, R&D Systems) and Interleukin-13 (IL-13, 20ng/mL, Peprotech), respectively, for 18h. Vehicle-treated (co-culture medium) cells were used as an unstimulated (M0) control.

To analyze the clustering of microglia upon pro-inflammatory and anti-inflammatory stimulation, RFP-positive microglia were imaged directly before the addition of M1/M2 inducing agents, and at 9h and 18h post-stimulation using the Cell Observer spinning disc confocal microscope (55 stitched images, 10magnification). The number of individual microglial cells and size of microglial clusters was quantified using the analyze particle function in Fiji.

After stimulation with M1/M2-inducing agents, culture supernatants were collected and spun down at 1200g for 10min at 4C. Pooled samples from three different healthy control lines for each cell type were analyzed using the Proteome Profiler Human XL Cytokine Array Kit (R&D Systems) according to the manufacturers instructions. The signal was visualized on a ChemiDoc MP imaging system (Bio-Rad) and analyzed using ImageStudioLite v5.2.5 (LI-COR). Data was then plotted as arbitrary units using the pheatmap 1.0.12 package in RStudio 1.4.1103.

In addition, to confirm the relative expression of Serpin E1 and CHI3L1 in cell culture supernatants, the Human Human Chitinase 3-like 1 Quantikine ELISA Kit (DC3L10) and Human Serpin E1/PAI-1 Quantikine ELISA Kit (DSE100, both R&D Systems) were used according to the manufacturers instructions.

pNeuron, pMGL and co-cultures were plated and maintained in WillCo-dish Glass Bottom Dishes (WillCo Wells) for 14days. Calcium transients were measured using the fluorescent probe Fluo 4-AM according to the manufacturers instructions (ThermoFisher). Cells were incubated with 20M Fluo 4-AM resuspended in 0.2% dimethyl sulfoxide for 30min at RT in Live Imaging Solution (ThermoFisher). After a washing step with Live Imaging Solution, cells were allowed to calibrate at RT for 1520min before imaging. Ca2+ images were taken by fluorescence microscopy at RT. The dye was excited at 488nm and images were taken continuously with a baseline recorded for 30s before stimulation. The stimuli used for calcium release were 50mM KCl (Sigma-Aldrich) for 30s, followed by a washing step for one minute. Microglial calcium release was stimulated by 50M ADP (Merck) under continuous perfusion for 1min, followed by a 1-min wash. Analysis of fluorescence intensity was performed using Fiji. Fluorescence measurements are expressed as a ratio (F/Fo) of the mean change in fluorescence (F) at a pixel relative to the resting fluorescence at that pixel before stimulation (Fo). The responses were analysed in 2040 cells per culture.

MNs on DIV 3345 were maintained in a bath temperature of 25C in a solution containing 167mM NaCl, 2.4mM KCl, 1mM MgCl2, 10mM glucose, 10mM HEPES, and 2mM CaCl2 adjusted to a pH of 7.4 and 300mOsm. Electrodes with tip resistances between 3 and 7M were produced from borosilicate glass (0.86mm inner diameter; 1.5mm outer diameter). The electrode was filled with intracellular solution containing 140mMK-Gluconate, 6mM NaCl, 1mM EGTA, 10mM HEPES, 4mM MgATP, 0.5mM Na3GTP, adjusted to pH 7.3 and 290mOsm. Data acquisition was performed using a Multiclamp 700B amplifier, digidata 1550A and clampEx 6 software (pCLAMP Software suite, Molecular Devices). Data was filtered at 2kHz and digitized at 10kHz. Series resistance (Rs) was continuously monitored and only recordings with stable<50 M and Rs<20% were included in the analysis. Voltage gated channel currents were measured on voltage clamp, neurons were pre-pulsed for 250ms with 140mV and subsequently a 10mV-step voltage was applied from 70 to+70mV. Induced action potentials were recorded on current clamp, neurons were held at 70mV and 8 voltage steps of 10mV, from 10 to 60mV, were applied. Data was analyzed using Clampfit 10.7 (pCLAMP Software suite).

Statistical analyses were conducted using GraphPad Prism 9 (GraphPad Software, San Diego, California USA, http://www.graphpad.com). Comparisons of two groups were performed by two-tailed unpaired t-tests and multiple group comparisons by one-way or two-way analysis of variance (ANOVA) with appropriate post-hoc tests as indicated in the figure legends. The statistical test and number of independent experiments used for each analysis are indicated in each figure legend. Data are presented as single data points and meansSEM. Differences were considered significant when P<0.05 (*P<0.05; **P<0.01; ***P<0.001; ns: not significant). GraphPad Prism 9 or RStudio 1.4.1103 were used to plot data. Final assembly and preparation of all figures was done using Adobe Illustrator 25.4.1.

Read this article:
Human iPSC co-culture model to investigate the interaction between microglia and motor neurons | Scientific Reports - Nature.com

What lab-grown cerebral organoids are revealing about the brain – New Scientist

Blobs of human brain cells cultivated in the lab, known as brain organoids or mini-brains, are transforming our understanding of neural development and disease. Now, researchers are working to make them more like the real thing

By Clare Wilson

Neil Webb

A DOZEN tiny, creamy balls are suspended in a dish of clear, pink liquid. Seen with the naked eye, they are amorphous blobs. But under a powerful microscope, and with some clever staining, their internal complexity is revealed: intricate whorls and layers of red, blue and green.

These are human brain cells, complete with branching outgrowths that have connected with one other, sparking electrical impulses. This is the stuff that thoughts are made of. And yet, these collections of cells were made in a laboratory in this case, in the lab of Madeline Lancaster at the University of Cambridge.

The structures, known as brain organoids or sometimes mini-brains, hold immense promise for helping us understand the brain. They have already produced fresh insights into how this most mysterious organ functions, how it differs in people with autism and how it goes awry in conditions such as dementia and motor neurone disease. They have even been made to grow primitive eyes.

To truly fulfill the potential of mini-brains, however, neuroscientists want to make them bigger and more complex. Some are attempting to grow them with blood vessels. Others are fusing two organoids, each mimicking a different part of the brain. Should they succeed, their lab-grown brains could model development and disease in the real thing in greater detail than ever before, paving the way to new insights and treatments.

But as researchers seek to make mini-brains genuinely worthy of the name, they move ever closer to a crucial question: at what point will their creations approach sentience?

The key to developing organoids was the discovery of stem cells,

More here:
What lab-grown cerebral organoids are revealing about the brain - New Scientist

Dean Kamen on the power of celebrating your own obsoletion – TechCrunch

More than 40 years and 1,000 or so patents after selling his first company, AutoSyringe, to healthcare giant Baxter, Dean Kamen still gets a charge describing breakthrough innovation. Its been five years since his organ fabricating project ARMI (Advanced Regenerative Manufacturing Institute) divided critics.

The project made more waves early last month, at the CNN-hosted conference Life Itself. Kamen paints the picture appearing on a panel at TC Sessions: Robotics today:

Doris Taylor, who moved up here from where she spent more than a decade in Texas, at the Texas Heart Institute, she gets on stage with a beaker. In the beaker is a miniature, pediatric-scale beating heart that was manufactured with induced pluripotent stem cells were put into a scaffold of preexisting organ. Within an hour of that presentation, Martine Rothblatt, the founder and chairman of United Therapeutics, is on stage and they roll out from backstage an almost surrealistic, lit from the top of the box. A panel opens, and what emerges out of the top of this platform is a scaffold of a human lung, that was printed, entirely printed at the smallest scale any printer has ever operated.

Inventor Dean Kamen looks on as over 110,000 pounds of personal protective equipment (PPE), shipped from Shanghai, China, is unloaded from a cargo plane at Manchester-Boston Regional Airport in Manchester, New Hampshire, Thursday, April 30, 2020. The equipment will be used for medical workers and first responders in their fight against the virus outbreak. (AP Photo/Charles Krupa)

Kamen is first to admit, however, that the path to all success is paved with failure. The trick is learning the right lesson.

What Ive learned from failure is go back and decide was the fundamental goal wrong thats why it failed, you succeeded, but nobody needs this or did the available technology and your systems integration and application have it wrong, in which case, youve now learned enough, go try again, go use a different approach, Kamen explains. Pick yourself up, try again, using a different approach. And it really doesnt matter how many times you fall down. If you fall down five times, but you stand up six, its okay. And in the end, you only need a win every once in a while to keep your confidence up. And hopefully, to give you the resources to keep going even though inevitably youll have failures, let the projects fail, dont let the people fail.

These are among the fundamentals Kamen has attempted to infuse into FIRST, the education program he co-founded in 1989, with MIT professor Woodie Flowers. It is best known for its robotics competitions, which center around competitive builds of robots and other projects, bringing the teamwork and enthusiasm of sports to STEM education subjects that might otherwise turn off students who traditionally encounter them in more formal and staid settings.

Kids wont go to class, or theyll take math for 45 minutes between phonics and spelling, one day a week. But theyll go after school for three hourse, every single day to get better at football or get better at basketball. So I said, look, were not competing for the hearts and minds of kids with the science fair and the spelling bee, were competing with the things that they invest all of their time, energy and passion in. So lets use that model make it aspirational, make it after school. Dont give them quizzes and tests, give them letters and trophies. Bring the school band and the mascots.

U.S. Sen. Jeanne Shaheen (D-NH), right, looks toward inventor Dean Kamen as over 110,000 pounds of personal protective equipment (PPE) from Shanghai, China, delivered to protect medical workers and first responders fighting the COVID-19 virus outbreak, is unloaded from a cargo plane at Manchester-Boston Regional Airport in Manchester, New Hampshire, Thursday, April 30, 2020. (AP Photo/Charles Krupa)

Perhaps the hardest-fought lesson of all, however, is understanding, accepting and even welcoming the fact that progress in technology and sciences means that one day your best work will be eclipsed.

You have to be more than prepared for it. You have to be confident it will happen, and you have to celebrate it. I celebrate it more when its me that obsoleted the last thing I did, but if somebody else can obsolete it and if I get to a point where I need a better clinical solution than a dialysis machine or an insulin pump, if I can get to a place with somebody elses technology to gave me a new organ or a prosthetic limb or something, I need to have a better quality of life, I will thank that person. And I hope I will return that favor by giving them something of value that we invented.

See the original post here:
Dean Kamen on the power of celebrating your own obsoletion - TechCrunch

Cell Culture Media Market Size Worth $10.2 Billion by 2030: Grand View Research, Inc. – PR Newswire

SAN FRANCISCO, July 21, 2022 /PRNewswire/ -- The global cell culture media market size is expected to reach USD 10.2 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.1% from 2022 to 2030. Expansion of biosimilars and biologics, growth in stem cell research, and emerging bio manufacturing technologies for cell-based vaccines are the major factors which are likely to drive the market. For instance, in October 2021, the Australian Government funded the Australian-led stem cell research through USD 25 million in grants.

Key Industry Insights & Findings from the report:

Read 150-page market research report, "Cell Culture Media Market Size, Share & Trends Analysis Report By Product (Serum-free Media, Classical Media), By Type (Liquid Media, Semi-solid And Solid Media), By Application, By End-user, By Region, And Segment Forecasts, 2022 - 2030", published by Grand View Research.

Cell Culture Media Market Growth & Trends

The expansion of clear, regulatory approval paths for biosimilars in emerging markets is generating great opportunities for biosimilar monoclonal antibodies. The availability of an approval pathway in the U.S., has led to new opportunities for bio manufacturers to enter major markets around the globe. Biosimilar versions of monoclonal antibodies have the probability to offer cost reductions of 25-30%, and many emerging market countries are vigorously developing pathways for approvals and are swiftly catching up. As this industry is expanding the key biopharmaceutical players are adopting robust culturing technologies to meet the increasing demand; thereby driving the growth of the market.

Moreover, there is growing interest in improving the stem cell culture, because this technology is being used extensively in research for studying the stem cell biology, as well as for therapeutic applications. Furthermore, funding related to this research field has augmented in recent years which has accelerated the growth of the market. In addition to this, key media manufacturers launched new products for stem cell research. For instance, in September 2021, Bio-Techne Corporation launched a novel medium for the maintenance and expansion of induced pluripotent stem cells having applications in both translational and research workflows.

The outbreak of COVID-19 pandemic has improved the demand for well-established cell-based vaccine production technologies. Moreover, it has given rise to a few scientific innovations, particularly in the production and testing of vaccine technology. For instance, the Vero line originated from the African green monkey kidney and has been extensively used for viral vaccine manufacturing. It has also been used for the development of various SARS-CoV variants. ProVeroTM1 Serum-free Medium is one such medium manufactured by Lonza Bioscience which is protein-free, and of non-animal origin designed to support the growth of Vero cells and MDCK.

Moreover, in many European countries, cell-based flu vaccines have been approved. A probable advantage of cell culture technology is that it authorizes faster start-up of the manufacturing of vaccines during the pandemic. Today, the development of superior biological models, the optimization of culture growth medium, and the reduced dependence on animal-derived components endure to drive the rapidly developing vaccine development.

On the other hand, ethical issues concerning the use of animal-derived products hinders the industry growth. For instance, FBS is collected from the blood of fetal calves is one of the major ethical issues of serum containing media. It is projected that 600,000 liters of FBS is achieved from up to 1.8 million bovine fetuses are produced globally every year, presenting momentous scientific and ethical challenges. To overcome this issue, numerous workshops were held in the past on the replacement of fetal bovine serum and possible ways to reduce the use of FBS in media.

Cell Culture Media Market Segmentation

Grand View Research has segmented the global cell culture media market based on product, application, type, end-user, and region:

Cell Culture MediaMarket - Product Outlook (Revenue, USD Million, 2018 - 2030)

Cell Culture MediaMarket - Application Outlook (Revenue, USD Million, 2018 - 2030)

Cell Culture MediaMarket - Type Outlook (Revenue, USD Million, 2018 - 2030)

Cell Culture MediaMarket - End-user Outlook (Revenue, USD Million, 2018 - 2030)

Cell Culture MediaMarket - Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)

List of Key Players of Cell Culture Media Market

Check out more related studies published by Grand View Research:

Browse through Grand View Research's Biotechnology Industry Research Reports.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James Corporate Sales Specialist, USA Grand View Research, Inc. Phone: +1-415-349-0058 Toll Free: 1-888-202-9519 Email: [emailprotected] Web: https://www.grandviewresearch.com Grand View Compass| Astra ESG Solutions Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg

SOURCE Grand View Research, Inc.

See the original post here:
Cell Culture Media Market Size Worth $10.2 Billion by 2030: Grand View Research, Inc. - PR Newswire

Enzyme Replacement Therapy Market Worth $15.18 Billion by 2028 at 6.8% CAGR Led by Hospitals Segment (49% Market Share in 2021) Global Analysis by The…

The Insight Partners

The global enzyme replacement therapy market size is expected to grow from $9.67 Billion in 2021 to $15.18 Billion by 2028; it is estimated to grow at a CAGR of 6.8% from 2022 to 2028.

New York, July 22, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Enzyme Type (Alglucosidase Alfa, Agalsidase Beta, Imiglucerase, Idursulfase, Galsulfase, Velaglucerase Alfa, and Other Enzymes), Therapeutic Conditions (Gaucher's Disease, Fabry's Disease, MPS, Pompe's Disease, SCID, and Other Therapeutic Conditions), Route of Administration (Parenteral and Oral), and End User (Hospitals, Infusion Centers, and Others), the global enzyme replacement therapy market research report provides deep dive regional and country level analysis of 18+ countries across 5 key regions, 30+ key company profiles, detailed SWOT and PEST analysis, in-depth market segmentation and industry landscape to provide latest market initiatives and competitive landscape, impact of COVID-19 pandemic on ecosystem.

Download PDF Brochure of Enzyme Replacement Therapy Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.theinsightpartners.com/sample/TIPRE00008474/

Enzyme Replacement Therapy Market Report Scope & Strategic Insights:

Report Coverage

Details

Market Size Value in

US$ 9.67 Billion in 2021

Market Size Value by

US$ 15.18 Billion by 2028

Growth rate

CAGR of 6.8% from 2022 to 2028

Forecast Period

2022-2028

Base Year

2021

No. of Pages

226

No. Tables

111

No. of Charts & Figures

86

Historical data available

Yes

Segments covered

Enzyme Type, Therapeutic Conditions, Route of Administration, and End-User

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Global Enzyme Replacement Therapy Market: Competitive Landscape and Key Developments Takeda Pharmaceutical Company Limited; Sanofi S.A.; AbbVie Inc.; BioMarin Pharmaceutical Inc.; Amicus Therapeutics; Alexion Pharmaceuticals, Inc. (AstraZeneca); Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.); Recordati S.p.A.; Pfizer Inc.; and CHIESI Farmaceutici S.p.A are among the key companies operating in the global enzyme replacement therapy market. Leading players focus on expanding and diversifying their market presence and clientele, thereby tapping prevailing business opportunities.

Story continues

Inquiry Before Purchase: https://www.theinsightpartners.com/inquiry/TIPRE00008474/

In September 2021, Takeda Pharmaceutical Company Limited signed a collaboration and partnership arrangement with JCR Pharmaceuticals Co., Ltd. to commercialize JR-141 outside of the US to treat Hunter syndrome.

In June 2019, BioMarin Pharmaceutical Inc. announced that Vimizim (elosulfase alfa) has been approved by the National Medical Products Administration (NMPA) for the treatment of patients suffering from mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. Vimizim is the first treatment in China approved for this condition.

Enzyme Replacement Therapy Market: Key Insights The enzyme replacement therapy market growth is attributed to the rising prevalence of lysosomal storage diseases (LSDs) and rapid regulatory approval with other marketing benefits for a drug with orphan drug designation. However, cutthroat competition among market players hinders overall market growth.

North America dominates the global enzyme replacement therapy market. The US holds the largest share of the market in the region due to the rising prevalence of LSDs and increasing regulatory approval of enzyme replacement therapy products. Intravenous (IV) infusions are used in enzyme replacement therapy to treat the underlying enzyme shortage that underlies rare diseases, including Gaucher, Fabry's, and Hunter's syndrome. Therefore, rising cases of these rare diseases propel the need for developing novel treatments.

Have a question? Speak to Research Analyst: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00008474

According to the National Organization for Rare Disorders (NORD), in 2021, males and females are equally affected by various types of Gaucher disease. Around 6,000 people in the US are suffering from Gaucher disease. Gaucher disease is the most prevalent genetic illness in the people of Ashkenazic Jewish origin. Its prevalence potentially hit 1 in 450 births. According to statistics released by the National Institute of Neurological Disorders and Stroke in August 2021, there are an estimated 32,950 instances of Pompe disease in the US, affecting one in 40,000 persons. The National Fabry Foundation estimates that there were around 7,713 Fabry patients in the US as of May 2020. Thus, the vast majority of rare diseases remain beyond possibilities of treatment and with continued research, it would be able to offer therapies to the affected patients. Therefore, this rise in the prevalence of rare diseases would drive the growth of the regional market in the coming years.

Rising Prevalence of LSDs and Rapid Regulatory Approval Positively Influence Overall Market Growth: Enzyme replacement therapy is performed to treat congenital enzyme deficiencies by using an enzyme or protein having enzymatic activity. The therapy is generally applied in rare and lysosomal storage diseases, including Pompe disease, Tay-Sachs disease, Fabry disease, Gaucher disease, and Hurler syndrome. Researchers and players are actively involved in the enzyme replacement therapy industry and are constantly focusing on advancing technologies that can offer better alternatives to conventional techniques.

In August 2021, the US Food and Drug Administration (FDA) approved Nexviazyme (avalglucosidase alfa-ngpt) for the treatment of patients aged one year and above suffering from late-onset Pompe disease. Nexviazyme is an ERT designed to specifically target the mannose-6-phosphate (M6P) receptor, the key pathway for cellular uptake of enzyme replacement therapy in Pompe disease. Nexviazyme has been shown in clinical trials to provide patients with improvements in respiratory function and walking distance.

Avail Lucrative DISCOUNTS on Enzyme Replacement Therapy Market Research Study: https://www.theinsightpartners.com/discount/TIPRE00008474/

In July 2019, Takeda Pharmaceutical Company launched an enzyme replacement therapy portfolio for LSD in India, expanding its range of rare disease therapies in the country. Under lysosomal storage disorders, India has been recording the prevalence of hunter syndrome, gaucher disease, and fabry disease. To address these, Takeda brought idursulfase for hunter syndrome, velaglucerase alpha for gaucher disease, and agalsidase alfa for fabry disease to the market. Such advancements and the rise in investments are propelling the global enzyme replacement therapy market growth significantly.

Global Enzyme Replacement Therapy Market: Segmental Overview Based on enzyme type, the global enzyme replacement therapy market is segmented into alglucosidase alfa, velaglucerase alfa, agalsidase beta, imiglucerase, galsulfase, idursulfase, and other enzymes. The others enzyme segment held the largest market share in 2021 and is anticipated to register the highest CAGR during 20222028. Based on therapeutic conditions, the market is segmented into Gaucher's disease, Fabry's disease, Pompe's disease, SCID, MPS, and other therapeutic conditions. The Gauchers disease segment held the largest market share in 2021 and is expected to register the highest CAGR during 20222028. Based on the route of administration, the global enzyme replacement therapy market is bifurcated into oral and parenteral. The parenteral segment held a larger market share in 2021 and is anticipated to register a higher CAGR during 20222028. Based on end users, the global enzyme replacement therapy market is segmented into hospitals, infusion centers, and others. The hospitals segment held the largest market share in 2021. However, the infusion centers segment is expected to register the highest CAGR during 20222028.

SARS-CoV-2 infection can cause a high risk for patients suffering from inborn errors of metabolism (IEM), since they often suffer from a multisystem disease, including respiratory and cardiovascular system involvement. Due to multi-systemic involvement, including crucial organs, people affected by rare metabolic abnormalities were at severe risk during the pandemic because of lysosomal dysfunction and inflammatory cascades activation. The major reason involved was the fear of getting infected at the hospital or during traveling to the hospital by using public transportation.

Directly Purchase Premium Copy of Enzyme Replacement Therapy Market Growth Report (2022-2028) at: https://www.theinsightpartners.com/buy/TIPRE00008474/

Many patients missed their infusions in March 2020, due to the inadequacy of hospital services dealing with the burden of COVID-19 patients. Patients claimed to feel anxious during hospital admissions or regarding drug supply, and studies revealed that they had depression and an increased amount of anxiety. Thus, the facts mentioned above indicate the overall negative impact of the COVID-19 pandemic on the global enzyme replacement therapy market.

Browse Adjoining Reports: Pompe Disease Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Late-Onset Pompe Disease, Classic Infantile-Onset Pompe Disease, Non-Classic infantile-onset Pompe Disease); Therapy (Enzyme Replacement Therapy, Gene Therapy, Others) and Geography

Pompe Disease Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Therapy Type (Enzyme Replacement Therapy, Substrate Reduction Therapy); Molecule Type (Biologics, Small Molecules); Route of Administration (Oral, Parenteral); Dosage Forms (Solid, Liquid) and Geography

Gaucher Disease Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Type (Neuropathic, Perinatal Lethal, Slow Neurogenic Decay); Treatment Approach (Enzyme Replacement Therapy, Substrate Reduction Therapy, Surgery); End Users (Hospitals, Ambulatory Surgical Centers, Clinical research institutes) and Geography

Gaucher Disease Drugs Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Disease Type ( Type I, Type II, Type III ); Treatment Type ( Enzyme Replacement Therapy (ERT), Substrate Reduction Treatment (SBT) ) and Geography

Fabry Disease Treatment Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Drug Type (Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT), Others)

Mucopolysaccharidosis Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Treatment (Enzyme Replacement Therapy, Stem Cell Therapy); MPS Type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, Others); End User (Hospitals, Specialty Clinics, Others) and Geography

Metabolic Disorders Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Gene Therapy, Drug Therapy, Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy); Indication (Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia); Route of Administration (Oral, Parenteral, Others), and Geography

Metabolism Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Therapy Type (Enzyme Replacement Therapy, Substrate Reduction Therapy, Small Molecule Drugs, Others); Application (Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism Disease, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Lysosomal Acid Lipase Deficiency Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Indication (Cholesteryl Ester Storage Disease (CESD), and Wolman Disease (WD)); Treatment Type (Liver Transplant, Enzyme Replacement Therapy, Lipid-Modifying Agents, and Others) and Geography

About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us: If you have any queries about this report or if you would like further information, please contact us:

Contact Person:Sameer Joshi E-mail: sales@theinsightpartners.com Phone:+1-646-491-9876 Press Release: https://www.theinsightpartners.com/pr/enzyme-replacement-therapy-market

Continue reading here:
Enzyme Replacement Therapy Market Worth $15.18 Billion by 2028 at 6.8% CAGR Led by Hospitals Segment (49% Market Share in 2021) Global Analysis by The...